RheumaGen Inc.

About RheumaGen Inc.

RheumaGen is a company dedicated to engineering a new class of therapeutics aimed at curing major autoimmune diseases. Their mission is to transform autoimmunity by editing the HLA or 'immune gene,' developing breakthrough cell and gene therapies to address the root causes of these conditions, and seeking cures and remission for patients.

Products & Services

Cell and Gene Therapies for Autoimmune Diseases:One-time, curative therapies targeting refractory or treatment-resistant rheumatoid arthritis (RA) and other autoimmune diseases such as progressive forms of multiple sclerosis, type 1 diabetes, and ankylosing spondylitis.

Specialties

Cell and Gene Therapies HLA Gene Editing Autoimmune Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-01-09 FD: 2025-01-09	2 investors

Series A Latest

2025-01-09

$15.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard Freed

CEO & Co-Founder

B

Brian Hart

COO & Co-Founder

B

Brian Freed

Professor, Medicine-Allergy/Clinical Immunology

R

Ryan Hart

Chief Legal Officer

T

Tate Hermanson

Vice President, Finance

B

B Robert Mozayeni

Chief Medical Officer

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

RheumaGen Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised